TRxADE HEALTH, Inc. (MEDS) is a provider of health facilities digitally. The company is engaged in the digitalization of the retail pharmacy experience by optimization of drug procurement. The company fosters price transparency and offers telehealth facilities to patients through its subsidiaries.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
MEDS stock price during the regular trading session of March 28, 2022, was $2.34 with a surge of 2.63%. Its price made an upward stride further as of the writing in the premarket session on March 29, 2022, by 23.07%.
MEDS: Key Financials
MEDS issued its Q4 2021 financial statement on March 28, 2022, for the three months ended December 31, 2021. Some of the key points are mentioned below.
The company posted total revenue of $2.4 million during Q4 2021 in comparison to $2.0 million during the same period of 2020. The company’s total revenue gained 19.7% over the year.
Net loss per share basic and diluted in Q4 2021 was $0.8 million or $0.10 corresponding to $2.3 million or $0.29 during the same period of 2020. The EPS of the company rocketed YoY.
MEDS: Events and Happenings
On March 15, 2022, MEDS reported its Executive management will participate in the Virtual 2022 Growth Conference being held on March 28-30, 2022. On February 23, 2022, MEDS updated that its subsidiary Bonum Health had entered into a Telemedicine Service Distribution contract with Coborn’s, Inc. According to the terms of the agreement, the company’s subsidiary will provide reasonable discount vouchers to customers of Coborn. The collaboration will also provide the patients of Coborn the discount savings directly via the company’s mobile app.
On February 15, 2022, MEDS announced its joint venture with SOSRx, LLC. SOSRx will provide biotherapeutics producers a single place to improve the sale and supply of their inventory to large biotherapeutics retailers. On February 9, 2022, MEDS informed the press regarding its Executive management’s participation at the Virtual Aegis Capital Corp. Conference held on February 24, 2022.
MEDS stock down fell in the past year considerably by 67%, the reason being the economic turmoil during the pandemic. Its stock rose by 22% in Tuesday’s premarket as the company announced its fourth-quarter financials and reported a gain in revenue and EPS over the year.